Inta Gribonika

Inta Gribonika

Auto-generated profile, based on publicly available information

Inta Gribonika

Metaorganism Immunity Section, Laboratory of Host Immunity and Microbiome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Science
Verified
Journal Article
Closed access
LCLiang Chi
Liang Chi
CLCan Liu
Can Liu
IGInta Gribonika
Inta Gribonika
JGJulia Gschwend
Julia Gschwend
DCDan Corral
Dan Corral
YBYasmine Belkaid
Yasmine Belkaid
Males and females exhibit profound differences in immune responses and disease susceptibility. However, the factors responsible for sex differences in tissue immunity remain poorly understood. Here, we uncovered a dominant role for type 2 innate lymphoid cells (ILC2s) in shaping sexual immune dimorphism within the skin. Mechanistically, negative regulation of ILC2s by androgens leads to a reduction in dendritic cell accumulation and activation in males, along with reduced tissue immunity. Collectively, our results reveal a role for the androgen-ILC2-dendritic cell axis in controlling sexual immune dimorphism. Moreover, this work proposes that tissue immune set points are defined by the dual action of sex hormones and the microbiota, with sex hormones controlling the strength of local immunity and microbiota calibrating its tone.

11 December 2024 in Nature
Verified
Journal Article
Open access
PDF file
IGInta Gribonika
Inta Gribonika
VBVictor I. Band
Victor I. Band
LCLiang Chi
Liang Chi
PPPaula Juliana Perez-Chaparro
Paula Juliana Perez-Chaparro
VLVerena M. Link
Verena M. Link
YBYasmine Belkaid
Yasmine Belkaid
The microbiota colonizes each barrier site and broadly controls host physiology1. However, when uncontrolled, microbial colonists can also promote inflammation and induce systemic infection2. The unique strategies employed at each barrier tissue to control the coexistence of the host with its microbiota remain largely elusive. Here we uncover that, within the skin, host-microbiota symbiosis depends on the remarkable ability of the skin to act as an autonomous lymphoid organ. Notably, an encounter with a new skin commensal promotes two parallel responses, both under the control of Langerhans cells. On one hand, skin commensals induce the formation of classical germinal centers within the lymph node associated with IgG1 and IgG3 antibody responses. On the other hand, microbial colonization also leads to the development of tertiary lymphoid organs within the skin that can locally sustain IgG2b and IgG2c responses. These phenomena are supported by the ability of regulatory T cells to convert into T follicular helper cells. Skin autonomous production of antibodies is sufficient to control local microbial biomass, as well as subsequent systemic infection with the same microbe. Collectively, these results reveal a striking compartmentalization of humoral responses to the microbiota allowing for control of both microbial symbiosis and potential pathogenesis.

11 December 2024 in Nature
Verified
Journal Article
Closed access
PDF file
DBDjenet Bousbaine
Djenet Bousbaine
KBKatherine D. Bauman
Katherine D. Bauman
YCY. Erin Chen
Y. Erin Chen
PLPranav V. Lalgudi
Pranav V. Lalgudi
TNTam T. D. Nguyen
Tam T. D. Nguyen
MFMichael A. Fischbach
Michael A. Fischbach

29 July 2022 in Science Immunology
Verified
Journal Article
Closed access
IGInta Gribonika
Inta Gribonika
ASAnneli Strömberg
Anneli Strömberg
CLCristina Lebrero-Fernandez
Cristina Lebrero-Fernandez
KSKarin Schön
Karin Schön
JMJames Moon
James Moon
NLNils Lycke
Nils Lycke
T helper 17 (T H 17) cells located at the Peyer’s patch (PP) inductive site and at the lamina propria effector site of the intestinal immune system are responsive to both pathogenic and commensal bacteria. Their plasticity to convert into follicular helper T (T FH ) cells has been proposed to be central to gut immunoglobulin A (IgA) responses. Here, we used an IL-17A fate reporter mouse and an MHC-II tetramer to analyze antigen-specific CD4 + T cell subsets and isolate them for single-cell RNA sequencing after oral immunization with cholera toxin and ovalbumin. We found a T FH -dominated response with only rare antigen-specific T H 17 cells (<8%) in the PP. A clonotypic analysis provided little support that clonotypes were shared between T FH and T H 17 cells, arguing against T H 17 plasticity as a major contributor to T FH differentiation. Two mouse models of T H 17 deficiency confirmed that gut IgA responses to oral immunization do not require T H 17 cells, with CD4 Cre Rorc fl/fl mice exhibiting normal germinal centers in PP and unperturbed total IgA production in the intestine.

19 May 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
Kyong-su ParkKyong-su Park
Kyong-su Park
KSKristina Svennerholm
Kristina Svennerholm
RCRossella Crescitelli
Rossella Crescitelli
CLCecilia Lässer
Cecilia Lässer
IGInta Gribonika
Inta Gribonika
JLJan Olof Lötvall
Jan Olof Lötvall
The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with Pseudomonas aeruginosa-derived SyBV protected mice against bacterial challenge, and this was accompanied by significant reduction in lung cell infiltration and inflammatory cytokines. Further, immunization with Escherichia coli-derived SyBV protected mice against E. coli sepsis, comparable to OMV-immunized group. The protective activity of SyBV was driven by the stimulation of B-cell and T-cell immunity. Also, SyBV were engineered to display the SARS-CoV-2 S1 protein on their surface, and these vesicles induced specific S1 protein antibody and T-cell responses. Collectively, these results demonstrate that SyBV may be a safe and efficient vaccine platform for the prevention of bacterial and viral infections.

29 March 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YBYoshita Bhide
Yoshita Bhide
WDWei Dong
Wei Dong
IGInta Gribonika
Inta Gribonika
DVDaniëlle Voshart
Daniëlle Voshart
TMTjarko Meijerhof
Tjarko Meijerhof
AHAnke Huckriede
Anke Huckriede
Adjuvanted whole inactivated virus (WIV) influenza vaccines show promise as broadly protective influenza vaccine candidates. Using WIV as basis we assessed the relative efficacy of different adjuvants by carrying out a head-to-head comparison of the liposome-based adjuvants CAF01 and CAF09 and the protein-based adjuvants CTA1-DD and CTA1-3M2e-DD and evaluated whether one or more of the adjuvants could induce broadly protective immunity. Mice were immunized with WIV prepared from A/Puerto Rico/8/34 (H1N1) virus intramuscularly with or without CAF01 or intranasally with or without CAF09, CTA1-DD, or CTA1-3M2e-DD, followed by challenge with homologous, heterologous or heterosubtypic virus. In general, intranasal immunizations were significantly more effective than intramuscular immunizations in inducing virus-specific serum-IgG, mucosal-IgA, and splenic IFNγ-producing CD4 T cells. Intranasal immunizations with adjuvanted vaccines afforded strong cross-protection with milder clinical symptoms and better control of virus load in lungs. Mechanistic studies indicated that non-neutralizing IgG antibodies and CD4 T cells were responsible for the improved cross-protection while IgA antibodies were dispensable. The role of CD4 T cells was particularly pronounced for CTA1-3M2e-DD adjuvanted vaccine as evidenced by CD4 T cell-dependent reduction of lung virus titers and clinical symptoms. Thus, intranasally administered WIV in combination with effective mucosal adjuvants appears to be a promising broadly protective influenza vaccine candidate.